In recent years, transcatheter aortic valve implantation (TAVI) has evolved from a treatment for patients who are inoperable or at high risk of surgical complications, to an equivalent alternative to surgical valve replacement for almost all patients with symptomatic, severe aortic valve stenosis. In the Netherlands, the number of patients who undergo TAVI gradually increases, while outcomes after TAVI improve and complication rates decrease. Before TAVI can be considered as the preferred treatment for aortic valve stenosis, however, additional insight is needed in valve durability, selection criteria for patients who benefit most from TAVI, and treatment outcomes regarding quality of life.
Conflict of interest and financial support: potential conflicts of interest have been reported for this article. ICMJE forms provided by the authors are available online along with the full text of this article.